Current Report Filing (8-k)
April 05 2017 - 5:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
April 5, 2017
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36792
|
|
98-0373793
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
7 Deer Park Drive, Suite K,
Monmouth Junction, New Jersey
|
08852
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (
732) 329-8885
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On April 5, 2017, CytoSorbents Corporation,
a Delaware corporation (the "Company") completed its previously announced sale of an aggregate of 2,222,222 shares of
common stock pursuant to the Company's existing shelf registration statement (File No. 333-205806) on Form S-3. The Company received
gross proceeds of approximately $10,000,000, based on a public offering price of $4.50 per share. After deducting the underwriting
discounts and commissions and estimated expenses related to the offering, the Company received net proceeds of approximately $8,900,000.
Cowen and Company acted as the sole book-running manager and representative of the underwriters for the offering. Aegis Capital
Corp, H.C. Wainwright & Co., B. Riley & Co., Maxim Group LLC and Northland Capital Markets acted as co-managers for the
offering.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit No.
|
Description.
|
|
|
5.1
|
Opinion of DLA Piper LLP (US).
|
|
|
23.1
|
Consent of DLA Piper LLP (US) (included in Exhibit 5.1).
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 5, 2017
|
CYTOSORBENTS CORPORATION
|
|
|
|
|
By:
|
/s/ Dr. Phillip P. Chan
|
|
Name:
|
Dr. Phillip P. Chan
|
|
Title:
|
President and
Chief Executive Officer
|
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Apr 2023 to Apr 2024